BioStem Technologies's ROE % for the quarter that ended in Sep. 2025 was 6.70%. BioStem Technologies's PB Ratio for the quarter that ended in Sep. 2025 was 1.57.
BioStem Technologies's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was 4.27%.
BioStem Technologies ROE % Adjusted to Book Value Related Terms
BioStem Technologies ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies ROE % Adjusted to Book Value Chart
BSEM vs TCRX, BYSI, MCRB: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, BioStem Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 4.27% mean?
BioStem Technologies (BSEM) has a ROE % Adjusted to Book Value of 4.27% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' ROE % Adjusted to Book Value too high?
BioStem Technologies' current ROE % Adjusted to Book Value is 4.27%. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' ROE % Adjusted to Book Value compare to TCRX and BYSI?
BioStem Technologies' ROE % Adjusted to Book Value of 4.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current ROE % Adjusted to Book Value is 4.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.59 — trading 97.4% below its estimated fair value. The current ROE % Adjusted to Book Value is 4.27%. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current ROE % Adjusted to Book Value is 4.27% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.59 is trading 97.4% below its estimated GF Value™ of $139.96.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
ROE % Adjusted to Book Value: 4.27%
GF Value™: $139.96 vs. price of $3.59 (97.4% below fair value)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
